SBX 1052
Benign Prostatic Hyperplasia (Prostate gland enlargement)
Early-stage ClinicalActive
Key Facts
Indication
Benign Prostatic Hyperplasia (Prostate gland enlargement)
Phase
Early-stage Clinical
Status
Active
Company
About Stramsen Biotech
Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.
View full company profile